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IntroductIon
Irritable bowel syndrome (IBS) is a functional bowel disorder, as 
defined by no identifiable structural or biochemical abnormality 
to explain the symptoms on routine clinical tests [1]. Epidemio-
logical surveys suggest that IBS is common, with a pooled global 
prevalence of 11.2%, shows a female preponderance, and mainly 
affects younger individuals [1–3]. IBS is frequently encountered 
in clinical practice, accounting for almost a third of all gastroen-
terology cases seen in primary care, with a subsequent third of 
these being referred onto secondary care for further evaluation 
[4]. The burden of illness with IBS is significant due to its chronic 
remitting-relapsing nature and its association with extra-intesti-
nal symptoms such fatigue, anxiety, depression, and somatisation, 
as well as diminished quality of life [5]. The exact cause of IBS is 
unknown although the prevailing hypothesis is a disorder of gut–
brain interaction as demonstrated by alterations in gut immunity, 
visceral hypersensitivity, enteric motor function disturbances, 
and central pain processing [5].
Guidelines for the management of IBS recommend the use of 
symptom-based criteria to aid clinicians towards making a positive 
diagnosis of IBS without the need to perform extensive investiga-
tions [6, 7]. Over the last 30 years this guidance have been pro-
vided by the Rome Foundation, an international panel of experts 
working in the field of functional gastrointestinal (GI) disorders, 
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who update criteria for functional GI disorders every decade or so 
following the accumulation of high-quality scientific data.
As of May 2016 the Rome IV criteria for functional GI disorders 
was released, within which there was a change in symptom-based 
criteria for IBS compared to the previous Rome III definition 
(Table 1) [8, 9]. The two main differences to emerge from Rome III 
to Rome IV criteria pertinent to IBS are:
(1) The term “abdominal discomfort” has been removed, leaving
just “abdominal pain.” The justifications for removing
discomfort were in view of its ambiguous interpretation, as
it can also be perceived as bloating, gas, fullness, sensation of
incomplete evacuation, and urgency [10]. Moreover, not all
languages have a word for discomfort.
(2) The symptom frequency has increased from at least 3 days/
month to at least 1 day/week, based on normative data from
a survey of adults without GI disorders, who in 95% of cases
reported experiencing abdominal pain less than 1 day/week
[11].
As a consequence of the change in criteria it can be envisaged 
that a subset of subjects previously diagnosed with IBS using the 
Rome III criteria will no longer be defined as having IBS accord-
ing to the Rome IV criteria. Indeed, this has now been evaluated 
by two recent studies [12, 13]. The first from a tertiary care centre 
in China found that roughly 50% of their subjects with Rome III 
defined IBS will not have IBS according to Rome IV, due to two-
thirds of these reporting only abdominal discomfort and one-third 
having infrequent pain [12]. Moreover, this study compared those 
who were now Rome IV-positive for IBS against those who were 
Rome IV-negative, finding that Rome IV-positive subjects experi-
enced more pain and higher overall IBS symptom severity scores, 
but no differences were noted for demographic characteristics, 
abdominal bloating, stool frequency, IBS subtype, disease dura-
tion, surgeries, or GI infection history [12]. A second study from 
The Netherlands, involving primary and secondary care subjects 
with Rome III IBS, noted that 87% could be defined as Rome IV-
positive IBS and that (compared to Rome IV-negative) this group 
were more often female, younger, had more severe GI symptoma-
tology (including abdominal bloating), visceral hypersensitivity, 
psychological co-morbidities, and lower general quality of life [13]. 
In all, these two studies share similarities but there were discrepan-
cies with regards to the proportion of Rome III IBS subjects that 
fulfil Rome IV criteria for IBS, female demographics, and the asso-
ciation with abdominal bloating.
Hence, in view of the recent change in IBS definition, and the 
relative paucity of data with some conflicting findings, further 
studies are needed to substantiate how the change in diagnostic 
criteria for IBS from Rome III to Rome IV impacts on gastroen-
terology practise with regards to clinical characteristics and patho-
physiological factors. We sought to address this issue using data 
from a large, well-characterised, cohort of Rome III IBS patients 
attending a Swedish gastroenterology centre.
MaterIalS and MetHodS
Rome III IBS subjects
We included subjects with IBS according to the Rome III criteria 
[8], who participated in studies assessing the relevance of patho-
physiological factors for symptoms in IBS [14–17]. The patients 
in this study cohort were recruited from the outpatient clinic 
specialised in functional GI disorders at the Sahlgrenska Univer-
sity Hospital in Gothenburg, Sweden. The majority of them were 
referred to the unit by their general practitioner or through self-
referral. The diagnosis of IBS was based on a typical clinical pres-
entation, fulfilment of Rome III criteria [8], and any additional 
investigations if considered necessary being negative. Subtyping 
according to the Rome III criteria was based on information from 
a 2-week stool diary using the Bristol Stool Form scale (BSF) 
[8, 18]. Exclusion criteria were: other GI disease(s) explaining the 
patient’s symptoms; other severe disease(s) such as malignancy, 
severe heart disease, kidney disease, or neurological disease; 
symptoms indicating other severe disease(s) such as GI bleeding, 
weight loss or fever; severe psychiatric disease; a history of drug or 
alcohol abuse within 6 months prior to enrolment; or pregnancy 
at the time of the study.
All patients were given study-specific verbal and written 
information before giving their written consent to participate in 
the studies. The Regional Ethical Review Board in Gothenburg 
approved the study prior to the start of patient enrolment. Parti-
cipants then completed questionnaires followed by undertaking 
relevant pathophysiological studies over the ensuing few weeks. 
The patients were naive to IBS medication during this time 
period.
Identification of Rome IV IBS-positive and -negative subjects
At baseline, Rome III IBS subjects completed the IBS Severity 
Scoring System (IBS-SSS) questionnaire [19], of which one ques-
tion asks “please enter the number of days you get abdominal pain 
in the last 10 days.” The answer to this question was used as a 
surrogate marker to identify those who could be categorised as 
having IBS according to Rome IV. In those who answered 0 or 1 
day this was considered as not fulfilling criteria for Rome IV IBS, 
in that (a) 0 days implies that these subjects with Rome III IBS 
Table 1 The Rome III and Rome IV diagnostic criteria for IBS [8, 9]
Rome III Rome IV
Recurrent abdominal pain or dis-
comfort at least 3 days/month in the 
last 3 months associated with two or 
more of the following criteria:
Recurrent abdominal pain on aver-
age at least 1 day/week in the last 
3 months, associated with two or 
more of the following criteria:
1. Improvement with defecation 1. Related to defecation
2. Onset associated with a change
in frequency of stool
2. Associated with a change in
frequency of stool
3. Onset associated with a change
in form (appearance) of stool
3. Associated with a change in
form (appearance) of stool
note: criteria fulfilled for the last 3 months with symptom onset at least 6 months 
prior to diagnosis
do not have abdominal pain but rather discomfort, and (b) 1 day 
of pain in 10 days suggests infrequent symptoms, which is less 
than once weekly. In contrast, those who answered having 2 or 
more days of abdominal pain in the last 10 days were categorised 
as being positive for Rome IV IBS as their symptom frequency 
would be considered to be at least weekly.
Questionnaires
Demographics. Basic demographic information about partici-
pants was obtained by a study nurse/research coordinator, using 
standardised case report forms. Of these variables, age and gender 
were used in the analyses in this study.
GI symptoms. The severity of IBS symptoms was evaluated with 
the widely used and validated questionnaire, IBS-SSS [19]. This 
questionnaire is based on five items assessing symptoms over the 
last 10 days; frequency and severity of abdominal pain, severity 
of abdominal distension, bowel habit dissatisfaction, and interfer-
ence of IBS with daily life. The questionnaire uses visual analogue 
scales and each item is scored 0–100, which yields a total score 
ranging from 0 to 500, with higher scores reflecting more severe 
symptoms. According to validated cut-off levels, the patients can 
be categorised as having mild IBS (score of <175), moderate IBS 
(175–300), or severe IBS (>300).
In this study, we analysed the total IBS-SSS score for the entire 
cohort and used it for descriptive purposes. However, as the 
subsequent identification o f R ome I V-positive o r - negative I BS 
stemmed from using a question from the IBS-SSS questionnaire 
(as mentioned above, the number of days of abdominal pain in the 
last 10 days), we did not use total IBS-SSS scores in the Rome IV 
subgroups; instead, we only analysed sub-scores pertaining to pain 
severity, severity of abdominal distension, bowel habit dissatisfac-
tion, and interference of IBS with daily life. Higher scores represent 
more severe symptoms.
Disease-specific quality of life. Th e 30-item IBS qu ality of  life 
questionnaire [20] measures, over the preceding month, nine 
quality of life domains found to be of relevance for IBS: emotional 
health, mental health, sleep, energy, physical functioning, food/
diet, social functioning, physical role, and sexual relations. Each 
scale score is transformed to a scale of 0–100, with 100 represent-
ing the best possible quality of life.
Psychological distress. The H ospital A nxiety a nd D epression  
scale [21] is a mood scale measuring symptoms over the  
last week. It has been developed for use in non-psychiatric  
clinical settings to identify patients with psychological distress. 
It consists of 14 items, evenly divided into two subscales, one for 
anxiety and one for depression. It uses a four-point Likert scale 
(0–3), which provides a minimum score of (no symptoms) and a 
maximum score of 21 (maximal severity of symptoms) on each 
subscale.
Somatisation. The Patient Health Questionnaire (PHQ)-12  
somatisation score [22] is a modified version of the widely used 
PHQ-15 somatisation questionnaire [23] that excludes the 
three 
GI symptoms (nausea, abdominal pain, and altered bowel habit), 
as these are likely to be directly related to functional GI disorders. 
Hence, the PHQ-12 only records bothersome non-GI symptoms 
over the previous month. The 12 symptoms assessed are back 
pain, limb pain, headaches, chest pain, dizziness, fainting spells, 
palpitations, breathlessness, menstrual cramps, dyspareunia, 
insomnia, and lethargy. Subjects completing the PHQ-12 were 
asked to rate how much they had been troubled by these 12 symp-
toms over the last 4 weeks as 0 (“not bothered at all”), 1 (“bothered 
a little”), or 2 (“bothered a lot”). The PHQ-12 responses can be 
used to calculate the overall severity of somatic symptoms, with 
higher scores representing greater somatisation.
Fatigue. The Fatigue Impact Scale [24] consists of a total of 40 
questions enquiring for the impact of fatigue over the preced-
ing month. The questions can be subdivided into three sections; 
physical functioning (ten items), cognitive functioning (ten 
items) and psychosocial functioning (20 items). Each item con-
sists of a statement, being rated by the subjects as 0 (no problem) 
to 4 (extreme problem). A higher score represents greater fatigue 
severity.
Physiologic measures
Rectal sensitivity. Balloon distensions using an electronic barostat 
(Dual Drive Barostat, Distender Series II; G&J Electronics 
Inc., Toronto, ON, Canada) were performed to assess colorectal 
sensitivity. In the year 2010, our department underwent a change 
in methodology to assess visceral sensitivity, with the phasic dis-
tension method being substituted by the ramp distension method. 
A detailed description of both these procedures has previously 
been reported [15, 17, 25].
In summary, for the initial Swedish cohort (n = 195), an ascend-
ing methods of limits paradigm with phasic distensions of 30 s 
duration separated by 30 s rest intervals with the balloon at the 
operating pressure was used [15]. Distensions were performed 
with 5 mmHg stepwise increments starting at the operating pres-
sure and increasing until the subject reported pain or when a pres-
sure level of 70 mmHg was reached. Thresholds for rectal fullness, 
urge to defecate, discomfort, and pain were determined, with sub-
jects subsequently rating on a visual analogue scale (VAS, 0–100) 
the severity of their symptoms, with higher scores representing 
greater severity. For the purpose of this study, only the pain thresh-
old (pressure, mmHg) and its corresponding VAS pain score are 
reported for the phasic distension method.
For the latter Swedish cohort patients (n = 143), an ascending 
method of limits ramp distension protocol starting at 0 mmHg 
and increasing in steps of 4 mmHg every minute up to the pain 
threshold or to a maximum balloon pressure of 60 mmHg was 
performed [17, 25]. Thresholds for first sensation, desire to 
defecate, urgency, and pain were assessed. Moreover, intensity rat-
ings of these symptoms at four different sensations during random 
phasic distensions of 12, 24, 36, and 48 mmHg above the operat-
ing pressure were also determined. For the purpose of this study 
only the pain threshold (pressure, mmHg), and VAS pain score at 
24 mmHg above the operating pressure, are reported for the ramp 
distension technique.
Colonic transit time. The ten radiopaque markers were ingested 
per day during six consecutive days, and on the morning of the 
7th day the remaining markers were counted using fluoroscopy 
(Exposcop 7000 Compact; Ziemh GmbH, Nüremberg, Germany) 
[26]. The colonic transit time in days was obtained by dividing the 
number of retained markers with the daily dose, i.e. 10.
Data analysis
Statistical analysis was carried out using SPSS version 21.0 soft-
ware (SPSS Inc. Chicago, Illinois, United States), with significance 
set at a p-value of <0.05. Data are presented as means ± standard 
deviations (SD) and proportions (%). As a first step we analysed 
the demographic profile of the Rome III IBS subjects. Following 
this, we identified the proportion of Rome III IBS subjects who 
could be considered as being positive or negative for Rome IV 
IBS based on the frequency of their abdominal pain. Thereafter, 
subsequent comparisons were made between these two groups 
pertaining to clinical symptoms and colorectal physiology, using 
the Student's T-test and Mann–Whitney U-test for parametric 
and non-parametric data, respectively. As a final step we used 
Spearman correlation to analyse how increasing number of days 
of abdominal pain correlated with clinical symptoms and colorec-
tal physiology.
reSultS
Subjects with Rome III IBS
We included 542 patients who fulfilled criteria for Rome III 
IBS, of which 402 (74%) were female. The mean age was 38 
years (SD 13), ranging from 18 to 72 years. The IBS subtypes 
based on the Rome III criteria (BSF) were diarrhoea (35%), 
constipation (25%), mixed (10%), unsubtyped (21%) with 
missing data for 9%. The IBS-SSS was mild in 9.8%, moder-
ate in 38.6%, and severe in 51.7%, with the overall mean score 
being 297 (SD 97).
The prevalence of Rome IV IBS within the Rome III IBS cohort
Figure 1 shows response to the question “please enter the number 
of days you get abdominal pain over the last 10 days.” No days with 
pain during the preceding 10 days were reported by 10% (n = 54) 
of the subjects, whereas 5% (n = 25) of the subjects reported they 
had 1 day with pain. Both of these groups were subsequently used 
to identify those subjects with Rome III IBS who would be con-
sidered as being negative for Rome IV IBS, giving a prevalence of 
15% (n = 79). The remaining 85% (n = 463) of Rome III IBS sub-
jects reported having pain ≥2 days per 10 days, which was used as 
a surrogate marker to identify those who would be considered as 
positive for Rome IV IBS.
Demographic and clinical comparison between Rome IV-positive 
and -negative IBS subjects
As Table  2 shows, Rome IV-positive IBS subjects had a greater 
proportion of females compared to their Rome IV-negative coun-
terparts. They also had increased pain severity, severity of abdo-
minal distension, interference with daily life, somatisation, 
and 
fatigue compared with Rome IV-negative IBS subjects. They also 
reported poorer disease-related quality of life scores within most 
domains (Fig. 2). However, there were no differences between the 
groups with regards to age, IBS subtype, bowel habit dissatisfac-
tion, anxiety, or depression.
Comparison of colorectal physiology between Rome IV-positive 
and -negative IBS subjects
With the phasic distension method, Rome IV-positive IBS sub-
jects recorded a trend towards lower pain threshold, and higher 
VAS pain scores at that corresponding threshold, than Rome IV-
negative IBS subjects. With the ramp distension method, Rome 
IV-positive IBS subjects recorded significantly lower pain thresh-
old, and higher VAS pain scores during the phasic distension at
24 mmHg above the operating pressure, than Rome IV-negative
IBS subjects. There were no differences in oro-anal transit times
between the groups (Table 3).
Correlation between number of abdominal pain days with 
clinical phenotype and colorectal physiology
As shown in Table 4, increasing number of days with abdominal 
pain during the preceding 10 days showed positive correlations 
with pain severity, severity of abdominal distension, bowel habit 
dissatisfaction, interference with daily life, poorer quality of life, 
fatigue, somatisation, and depression. There was also a reduction 
in pain thresholds and increasing VAS pain scores with increasing 


































Fig. 1 Subjects with Rome III IBS reporting the “number of days with 
abdominal pain in the last 10 days.” note: those reporting 0 or 1 day of 
pain were subsequently classed as not fulfilling the criteria required for 
Rome Iv IBS (i.e. Rome Iv IBS-negative) = 15%. Those reporting ≥2 days 
per 10 days were classed as fulfilling Rome Iv IBS criteria (i.e. Rome Iv 
IBS-positive) = 85%
dIScuSSIon
In this study, we evaluated the implications of updating the IBS 
diagnostic criteria from Rome III to Rome IV. We could demon-
strate that 85% of subjects with Rome III IBS who visited a gastro-
enterology outpatient clinic will still likely have IBS according to 
Rome IV, whereas 15% will not. Moreover, Rome IV-positive IBS 
patients demonstrated more severe clinical symptoms and height-
ened visceral sensitivity compared to Rome IV-negative subjects. 
Finally, we have shown that determining the number of days with 
abdominal pain over the last 10 days can in itself be a useful meas-
ure to predict visceral hypersensitivity and the overall severity of 
ill-health within IBS subjects.
First, based on the surrogate marker adopted in our study, most 
subjects with Rome III IBS in a Western Gastroenterology Clinic 
will not lose their diagnosis when transferring over to Rome IV, 
hence it will not have major implications in diagnostic coding. This 
data are consistent with that from The Netherlands where, after 
using a 14-day symptom diary to assess abdominal pain frequency, 
87% of Rome III IBS could be transferred over to Rome IV [13]. 
However, both these western studies contrast with that from a ter-
tiary care clinic in China where subjects concurrently completed 
both the Rome III and Rome IV diagnostic questionnaire; in 170 
patients fulfilling the Rome III criteria for IBS, 46% of these ful-
filled Rome IV criteria for IBS and 54% did not [12]. The reasons 
for not fulfilling Rome IV IBS status was due to roughly two-thirds 
reporting only abdominal discomfort and not pain, and one-third 
reporting infrequent pain [12]. The discrepancy between the stud-
ies from the East and West may be due to differences in methodo-
logical sampling or symptom-reporting behavioural pattern [27]. 
It has previously been shown that bloating is very common among 
Asian patients consulting in clinic [28], and that its uncomfortable 
nature may be reported as discomfort [27]. Indeed, the imprecise 
interpretation of the word “discomfort” across communities was 
fundamental in its removal from the latest iteration of IBS diag-
nostic criteria [9, 10].
Second, Rome IV-positive IBS subjects show a distinct clinical 
phenotype compared to Rome IV-negative patients. They are more 
likely to be female, demonstrate increased pain severity, abdomi-
nal distension, somatisation, fatigue, and generally poorer quality 
of life. Moreover, they experience greater visceral sensitivity. How-
ever, there were no differences between the groups with regards 
to psychological distress, bowel habit dissatisfaction, and oro-anal 
transit time. Our findings are largely in concordance with that 
produced from China and The Netherlands, although some differ-
ences were noted that warrant consideration.
For example, the group from China did not find any difference 
with regards to gender or abdominal distension between Rome 
IV-positive and -negative IBS subjects [12, 13]. Admittedly, the
relationship between gender and IBS symptoms is not straight for-
ward, with men and women sharing more similarities than differ-
ences [29]. Further, where differences have been noted the effect
size has been reported to be small [29]; in the instance of abdomi-
nal pain a meta-analysis has shown that women are more likely to
report pain than men (odds ratio 1.12, 95% CI 1.02–1.22) [30]. In
our study, the greater prevalence of females in Rome IV-positive
IBS subjects was only just significant (76 vs. 65%, p = 0.04), sup-
porting the notion that where gender differences are observed,
these are modest. Nevertheless, our findings may open the debate
as to why therapeutic studies in IBS have historically shown greater 
efficacy in females than in males [30, 31]. This has largely been
attributed to the natural history of IBS, leading to a far greater rep-
resentation of females compared to males within clinical trials [30,
31]. However, we also show that females are more homogeneous in 
their symptom profile with regards to having abdominal pain and
not discomfort, whereas males have a greater propensity to either.
It can be envisaged that the Rome IV criteria for IBS will at least
provide a more homogeneous group of patients, all of whom will
Table 2 Comparision between Rome IV-positive and -negative 




(n = 79, 15%)
Rome IV-positive 
IBS 
(n = 463, 85%)
p-value
Demographics
 Female 51 (65%) 351 (76%) 0.04
 Mean age (SD) 38.9 (13) 37.8 (13.4) 0.4
IBS Subtype (Rome III)
 Constipation 17 (22%) 118 (25%) 0.5
 Diarrhoea 31 (39%) 158 (34%)
 Mixed 5 (6%) 51 (11%)
 unsubtyped 20 (25%) 95 (21%)
 Missing 6 (8%) 41 (9%)
IBS-SSS (SD)
 Abdominal pain severity 17.0 (28.4) 52.5 (23.2) <0.001
 Abdominal distension 40.9 (30.2) 59.0 (26.7) 0.001
 Bowel habit dissatisfac-
tion
67.1 (27.7) 70.2 (24.7) 0.3
 Interference with 
daily life
58.6 (26) 68.2 (22.6) 0.001
HADS (SD)
 Anxiety 6.7 (4) 7.6 (4.7) 0.1
 Depression 5.1 (3.8) 5.6 (3.7) 0.3
 Total 11.8 (6.5) 13.1 (7.3) 0.15
PHQ-12 somatisation 
(SD)
5.9 (2.8) 8.7 (4.3) 0.01
Fatigue Impact Score (SD)
 Physical 8.4 (7.8) 14.4 (10.4) 0.02
 Cognitive 10.4 (8.7) 16.5 (11.3) 0.03
 Psychosocial 17.2 (17.1) 29 (19.7) 0.01
 Total 35.9 (31.7) 59.9 (39.4) 0.01
HADS Hospital Anxiety and Depression Scale, IBS-SSS IBS Severity Scoring 
System, P, HQ-12 Patient Health Questionnaire
have abdominal pain, irrespective of gender. However, results for 
men with IBS with probably still lag behind women due to issues 
with sample size. With regards to abdominal distension, the lack 
of significant difference seen in China between Rome IV-positive 
and -negative IBS groups may be due to the negative group largely 
being identified through having discomfort [12], which is com-
monly attributed to bloating [27, 28].
Next, the group from The Netherlands recorded higher psycho-
logical distress (in particular, for depression) in Rome IV-positive 
compared to -negative IBS subjects [13], which was not replicated 
in our study. This may be explained by patient recruitment in that 
subjects from The Netherlands with Rome IV-positive IBS were 
significantly more likely to be from secondary care, compared to 
their Rome IV-negative counterparts who had a large representa-
tion from primary care [13]. Previous studies have shown that dif-
ferences exist between IBS consulters in primary and secondary 
care with regards to symptom severity, quality of life, and psycho-
logical symptoms [32, 33]. A key strength of our study was that 
this potential confounding factor was absent, as all subjects were 
seen in specialist care. It is also important to bear in mind that 
subjects with Rome III IBS who are negative for Rome IV IBS are 
still symptomatic and are likely to be diagnosed with an alternate 
functional bowel disorder; the study from The Netherlands was 
able to redefine these subjects as having functional constipation in 
24%, functional diarrhoea in 34%, functional abdominal bloating/
distension in 26%, and no diagnosis in the remaining 16% [13]. 
Moreover, subjects with these “other” functional bowel disorders 
do report psychological distress, with a large secondary care study 
of Rome III defined subjects showing that although IBS was associ-
ated with greater anxiety compared to functional constipation or 
diarrhoea, there was no difference in prevalence rates of depres-
sion between the groups [34].
However, in general, our study along with that from China 
and The Netherlands do suggest that the removal of discomfort 
and infrequent abdominal pain from the current iteration of 
IBS criteria identifies a subset with more severe disease activity. 
Yet, the culmination of these recent studies may seem completely 

































Fig. 2 IBS quality of life (QOl) domains in Rome Iv-positive and -negative IBS subjects







Phasic distension barostat method
 Rectal pain threshold, 
mmHg (SD)
35.1 (14.1) 29.7 (11.9) 0.08
 vAS pain score at 
pain threshold, mm 
(SD)
28.1 (27.6) 34 (22.8) 0.06
Ramp distension barostat method
 Rectal pain threshold, 
mmHg (SD)
32 (10.1) 26.4 (8.3) 0.01
 vAS pain score at 
24 mmHg distension, 
mm (SD)
24.1 (31.3) 51.2 (30.8) 0.001
Oro-anal transit time, 
days (SD)
1.4 (0.8) 1.6 (1.0) 0.1
15 years ago, which evaluated subjects fulfilling Rome I criteria 
for IBS and compared those with pain-predominance and 
discomfort-predominance [35]. The investigators noted no 
difference in IBS symptom severity, psychological distress, 
quality of life, and healthcare utilisation between the groups. 
However, importantly, the groups were not completely exclusive 
as the division was based on predominant symptoms, meaning 
for example that subjects with discomfort-predominance did still 
have pain (~70%) [35]. Moreover, predominant symptoms in 
functional GI disorders can fluctuate, even over short periods of 
time [36].
Third, we noted that as the number of days with abdominal pain 
in the last 10 days increased, there was a significant correlation 
with visceral hypersensitivity and measures of ill-health related 
to intestinal and extra-intestinal manifestations of IBS. Indeed, a 
recent multi-cohort study has shown increasing visceral sensitiv-
ity to correlate positively with IBS symptoms, even after adjust-
ing for psychological distress or somatisation [17]. Furthermore, a 
randomised placebo-controlled double-blind study has shown that 
attenuating visceral hypersensitivity, through the histamine recep-
tor H1 antagonist Ebastine, leads to a parallel reduction in IBS 
symptoms [37]. Hence, asking about the frequency of abdominal 
pain over the preceding 10 days can be a simple and useful guide 
to gauge the overall severity of an individual’s ill-health, and may 
in future clinical practise potentially be used to select individuals 
for treatments that address visceral hypersensitivity. With this in 
regard, it may be argued that increasing the pain frequency thresh-
old further in Rome IV, to more than 1 day per week, will lead to 
greater homogeneity in IBS subjects; however, it is important to re-
emphasise that this cut-off, albeit from the United States only, was 
based on normative data from a survey of adults without GI dis-
orders, who in 95% of cases reported having abdominal pain less 
than 1 day per week. Finally, the frequency of abdominal pain did 
not correlate with oro-anal transit time, which is line with previous 
work from our group showing poor correlation between colonic 
transit time and abdominal pain in IBS, but instead good correla-
tion with the predominant bowel habit of the patient [26].
Our study may be perceived as being limited in that we used a 
surrogate marker, based on the number of days of abdominal pain 
in the last 10 days (from the IBS-SSS questionnaire), to identify 
those with Rome III IBS who can be classified as being positive or 
negative for Rome IV IBS. The reason for using this methodological 
process was due to having a large number of well-characterised his-
torical patients with Rome III IBS already under our care before the 
publication of Rome IV. Nevertheless, IBS has a remitting-relaps-
ing course and hence it is possible that some subjects completing 
the questionnaire may have been experiencing no or infrequent 
abdominal pain over the last 10 days and thus classed as not hav-
ing Rome IV IBS; yet, they may have had more frequent symptoms 
before then. Another issue is that, we identified Rome IV IBS based 
on subjects reporting ≥2 days of pain within the last 10 days, as this 
would suggest on average at least 1 day of pain per week as required 
for Rome IV. However, in its strictest sense, 2–3 days of pain per 10 
days may still not meet a pain frequency threshold of at least 1 day/
week if the days of pain were at the extremes of the 10 days and not 
in between. Future prospective studies may overcome this poten-
tial shortcoming by using 14-day symptom diaries.
Finally, our study raises additional questions. For example, whilst 
we investigated the major changes in IBS criteria from Rome III to 
IV, which being the removal of abdominal discomfort and increase 
in abdominal pain frequency to at least 1 day per week, we did 
not evaluate the subtle changes in criteria related to bowel habit 
(Table 1). The Rome III definition states that the onset of abdomi-
nal pain/discomfort to be associated with at least two of the fol-
lowing three: change in stool form, change in stool frequency, and 
improvement with defecation. However, Rome IV acknowledges 
Table 4 Correlation between increasing number of abdominal pain 






 Abdominal pain severity 0.50 <0.001
 Abdominal distension severity 0.30 <0.001
 Bowel habit dissatisfaction 0.14 0.001











 Mental health −0.17 <0.001
 Sleep −0.29 < 0.001
 Energy −0.31 <0.001
 Physical function −0.28 <0.001
 Food −0.19 <0.001
 Social Role −0.15 <0.001
 Physical Role −0.19 <0.001
 Sexual −0.27 <0.001
Phasic distension barostat method
 Rectal pain threshold −0.13 0.08
 vAS pain scores 0.14 0.05
Ramp distension barostat method
 Rectal pain thresholds −0.19 0.02
 vAS pain scores at 24 mmHg distension 0.33 <0.001
Oro-anal transit time −0.005 0.9
that some patients with IBS may experience worsening, and not an 
improvement, in abdominal pain following defecation. This cal-
culation is beyond the scope of our paper as Rome III does not 
carry information about exacerbation of abdominal symptoms 
with defecation. Another noteworthy point is that whilst we show 
the majority of Rome III IBS patients in gastroenterology care to 
retain their diagnosis when transferring over to Rome IV, our find-
ings may not be applicable to primary care where conceivably most 
patients with Rome III IBS will have milder symptoms. It is also 
unclear whether previous findings from Rome III IBS studies can 
be generalised to Rome IV IBS. Moreover, it is not yet known how 
the change in IBS criteria will impact on clinical management; it 
may be perceived that for Rome IV-positive IBS subjects interest 
will predominantly be directed towards attenuating pain plus asso-
ciated intestinal/extra-intestinal symptoms, whereas those who are 
negative for Rome IV IBS the emphasis will be towards diagnosing 
an alternate bowel disorder, such as functional constipation, and 
focusing on improving bowel habit. However, this remains specu-
lative and whether such an approach will lead to an improvement 
in clinical care, and justify the change in criteria, remains to be 
determined.
In conclusion, the update of criteria from Rome III to Rome IV 
will not have major implications in diagnostic coding in Western 
Gastroenterology Clinics, as only 15% of subjects with Rome III 
IBS will not fulfil Rome IV IBS criteria. Those who are positive for 
Rome IV IBS have more severe clinical symptoms and heightened 
visceral sensitivity, compared to Rome IV-negative IBS patients.
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Study Highlights
WhAT IS CuRRENT kNOWLEDGE
✓✓ the diagnostic criteria for IBS have been updated from
rome III to rome IV.
✓✓ there is a relative paucity of data, with some conflicting
findings, how this change in IBS criteria impacts on
clinical characteristics and pathophysiological factors.
WhAT IS NEW hERE
✓✓ overall, 85% of subjects with rome III defined IBS fulfil
criteria for rome IV IBS, but 15% do not.
✓✓ Hence, the update of IBS criteria from rome III to rome
IV will not have major implications in diagnostic coding in
Western Gastroenterology clinics.
✓✓ However, rome IV-positive IBS patients demonstrate
more severe clinical symptoms and heightened visceral
sensitivity compared to rome IV-negative subjects.
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